HEXADRONE
11.12.2023 08:31:35 CET | Business Wire | Press release
Hexadrone SAS, A French Modular UAV’s Manufacturer Created in 2014 has successfully completed GAP Analysis for The Tundra 2 in its Urban and Endurance versions versus DR EU 2019/945 with intension for Class Identification Label C5 and C6. With the achievement of this milestone, the certification process for both Urban and Endurance Version have been now formally triggered by Hexadrone to be performed by the notified body NavCert GmbH.
The Tundra 2 is bringing on the market a key differentiator by providing extreme modularity on UAVs, integrating unlimited type of payloads used in various sectors like, Surveillance, Geospatial, Agriculture, Oil and gas, Military, Homeland security, Rescue and much more.
“Through an in-depth analysis based on European Union (EU) Regulation 2019/945, we have ensured that the specifications of the Tundra 2 as well as our user manuals fully meet the current requirements. This compliance will ensure that the TUNDRA 2 users will be able to fly in European airspace legally, in accordance with categories C5 and C6, from 2024.
The exceptional modularity of the TUNDRA 2 offers reliable technical solutions for a variety of sectors. Due to its standardized interfaces, it can be easily extended using a multitude of addons while maintaining its compliance with current standards,”- says Alexandre Labesse, CEO of Hexadrone.
NavCert GmbH (NB 2603), currently chairs the coordination group of notified bodies for unmanned aircraft systems in accordance with the Delegated Regulation(EU) 2019/945. NavCert GmbH is one of the three entities in Europe which are appointed to perform C5/C6 class drone conformity tests, to be operated within the category specific, for performing operations Beyond Ground Observation (BGO) also known as Beyond Vision Line Of Sight (BVLOS).
Marcel Visser, CEO of NavCert GmbH, stated, “Congratulations to Hexadrone on being first confirming both multicopter C5 and C6 Drone specification compliancy to Delegated Regulation (EU) 2019/945. We are honored to be the Notified Body (NB 2603) selected by Hexadrone to perform Type Examinations for both version of the Tundra 2. Our extensive experience and our contribution to the development of the EN 4709 standard have been invaluable in conducting the technical assessments on unmanned aircraft systems for civil use. We remain dedicated to upholding the requisite standards of quality and safety for drone operations within the European Union."
*****
Starting 2024, Hexadrone is accelerating it’s worldwide expansion by selecting and recruiting Specialised resellers over the Globe.
About Hexadrone
Through its three Departments, Hexadrone is recognized as an expert in designing and manufacturing a modular UAV that gives customers a valuable investment for their activity. Founded in 2014, Hexadrone was initially providing a web platform to resel UAV components and quickly moved to the UAV custom assembling. Based on the user’s experiences feedback, Hexadrone has understood that a universal and modular platform was the answer to the market and after the first Version of the TUNDRA Hexadrone has built a factory to design and to manufacture a multi-purpose drone for professionals.
Today, the production capacity allowed to manufacture up to 1000 TUNDRA 2 units per year.
About NavCert GmbH
NavCert is the first laboratory ever accredited in Europe in the field of GNSS, nowadays with a flexible scope, a remarkable USP achievement. The firm provides worldwide technical services, like expert opinion, verification, validation, and voluntary certification services in the areas of precise positioning/localization, navigation, velocity and timing. Furthermore, NavCert is accredited as certification body for unmanned aircraft systems (UAS) by the Deutsche Akkreditierungsstelle (DAkkS) and is notified (NB 2603) by the German Federal Office of Civil Aeronautics for the EU Type Examination of fixed-wing, copter and multicopter UAS in classes C0 to C4 in the Open Category and C5 to C6 in the Specific Category according to the Delegated Regulation (EU) 2019/945 incl. referred standards. NavCert chairs the coordination group of notified bodies for UAS. These activities are complemented by GAP analysis of specification and documentation and pre-testing. For additional information, please visit NavCert website at www.navcert.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231210550915/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 15:07:00 CEST | Press release
Initial planning calls for Data Sciences Division to focus efforts in cyber secure infrastructure with dedication in fintech and patented Information Data Exchange® (IDE®) Management will harness its API Media acquisition, robust patent portfolio, ADIO® Inaudible Tones, WiSA® and Dolby® partnerships to establish worldwide acoustic industry standards in high-definition wireless transmission, spatial-audio control and interoperability Plan includes API media’s stand-alone and renewed execution of WiSA semiconductor and software modules strategy with an R&D effort targeted to new robotic and drone applications Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™,
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 14:50:00 CEST | Press release
First presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs)at the 2026 EADV SymposiumThe vast majority of patients achieving EASI50 at Week 8 and continuing double-blind, as needed treatment with Opzelura® (ruxolitinib) cream through Week 24 demonstrated disease control, with 84.3% achieving EASI75 (a ≥75% improvement in the Eczema Area and Severity Index score from baseline) and 70.6% achieving IGA-TS (Investigator’s Global Assessment Treatment Success)Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU), feedback expected in 1H 2026 Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with mode
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 14:03:00 CEST | Press release
Full data presented at ESOC 2026 further strengthen the clinical evidence supporting TIGERTRIEVER™ 13 for the treatment of distal vessel occlusion stroke — a segment representing nearly half of all ischemic strokes Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L
2 Million Downloads in Six Months: Tabelog’s Multilingual App Solves Critical Dining Pain Points for Travelers to Japan7.5.2026 14:00:00 CEST | Press release
“Eat Where Locals Eat” Making authentic Japanese dining experiences accessible to global travelers through instant reservations at over 70,000 restaurants nationwide. Tabelog (https://tabelog.com/en/), one of Japan’s largest (*1) restaurant search and reservation services operated by Kakaku.com, Inc., has announced that its multilingual smartphone app (iOS/Android) for travelers visiting Japan has reached 2 million downloads (*2). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507560248/en/ 2M+ Downloads in 6 Months. The app also ranked #1 in downloads among Restaurant Search Apps in Japan for International Travelers (*3) in Taiwan, Hong Kong, South Korea, and the U.S., reflecting its immense popularity among global visitors. Download URL: https://tabelog-tourists.onelink.me/3eEh/iqkkho9r The Trusted Choice for Global Travelers: Solving Two Major Dining Pain Points in Japan For years, international visitors to Japan have
Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development7.5.2026 14:00:00 CEST | Press release
Altasciences, a fully integrated drug development solution company, andCertara (Nasdaq: CERT), a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs. Fewer than half of preclinical drug candidates successfully reach first-in-human trials. Failures are driven by toxicity, poor pharmacokinetics, lack of efficacy, and challenges translating results from animals to humans. Many of these risks can be mitigated through a fully integrated model-informed drug development approach. Building on Altasciences’ Acceleration Platform, the integration of Certara’s strategic drug development services and biosimulation technology enables sponsors to establish proof of mechanism earlier, design more efficient studies, and make informed go/no-go decisions with greater confidence. By embedding modeling insights and digital workflows directly into development execution, study designs are optimized, dosing strategies
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom